Instrument Inactif

Autres langues Alteogen Inc Korea S.E.

Actions

Cours en clôture Korea S.E. Autres places de cotation
-	-

2023	Alteogen Inc. annonce que l'essai clinique de Tergase n'a révélé aucune incidence d'ADA	CI
2023	ALTEOGEN Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2023	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA	05/09/23
ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
ALTEOGEN Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23
Alteogen And Sandoz Enter A Biosimilars Agreement Relating To Subcutaneous Products	03/03/23
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen's Hybrozyme Technology	03/01/23
ALTEOGEN Inc. Enters into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by its Hybrozyme Technology	02/01/23
Alteogen Inc. Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients	08/03/21
Alteogen Enters Into Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled by Its Hybrozyme™ Technology	07/01/21
ALTEOGEN Inc. announced that it has received KRW 74.999925 billion in funding from SG Core Co., Ltd.	07/01/21
ALTEOGEN Inc. announced that it expects to receive KRW 74.999925 billion in funding from SG Core Co., Ltd.	14/12/20
ALTEOGEN Inc. announced that it has received KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation	12/11/20
ALTEOGEN Inc. announced that it expects to receive KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation	04/11/20
ALTEOGEN Inc.(KOSDAQ:A196170) added to FTSE All-World Index	21/09/20
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme Technology to Enable Subcutaneous Administration of Biologic Products	24/06/20
ALTEOGEN Inc. Presents the First-In-Human Data on Alt-P7, A Her2-Targeting Antibody-Drug Conjugate At ASCO 2020	29/05/20
Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of its Hybrozyme™ Technology to Enable Subcutaneous Administration of Biologic Products	02/12/19
Alteogen Inc. Signs Licensing Agreement with Cristalia Produtos Quimicos Farmaceuticos Ltda	23/07/19
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH	03/12/18
ALTEOGEN Inc. announced that it has received KRW 31.999718 billion in funding from KB Securities Co.,Ltd, Shinhan Investment Corp., Meritz Securities Co., Ltd., Korea Investment Holdings Co., Ltd., Kiwoom Securities Co., Ltd.	19/04/18
ALTEOGEN Inc. announced that it expects to receive KRW 31.999718 billion in funding from KB Securities Co.,Ltd, Shinhan Investment Corp., Meritz Securities Co., Ltd., Korea Investment Holdings Co., Ltd., Kiwoom Securities Co., Ltd.	12/04/18

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Alteogen Inc Korea S.E.

Actions

Autres langues

Filtres